Minoli, MartinaMartinaMinoli0000-0003-2924-4538Cantore, ThomasThomasCantoreHanhart, Daniel WalterDaniel WalterHanhart0000-0003-0665-8607Kiener, Mirjam SusannaMirjam SusannaKienerFedrizzi, TarcisioTarcisioFedrizziLa Manna, FedericoFedericoLa MannaKarkampouna, SofiaSofiaKarkampounaChouvardas, PanagiotisPanagiotisChouvardasGenitsch Gratwohl, VeraVeraGenitsch Gratwohl0000-0003-0919-7295Rodríguez Calero, José AntonioJosé AntonioRodríguez CaleroCompérat, EvaEvaCompératKlima, IrenaIrenaKlimaGasperini, PaolaPaolaGasperiniKiss, BernhardBernhardKissSeiler-Blarer, RolandRolandSeiler-BlarerDemichelis, FrancescaFrancescaDemichelisThalmann, GeorgeGeorgeThalmannKruithof-de Julio, MariannaMariannaKruithof-de Julio2024-10-252024-10-252023-04-18https://boris-portal.unibe.ch/handle/20.500.12422/166563Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal genetic landscapes, and consistently share key genetic alterations, mirroring tumor evolution in longitudinal sampling. Our drug screening pipeline is implemented using PDOs, testing standard-of-care and FDA-approved compounds for other tumors. Integrative analysis of drug response profiles with matched PDO genomic analysis is used to determine enrichment thresholds for candidate markers of therapy response and resistance. Finally, by assessing the clinical history of longitudinally sampled cases, we can determine whether the disease clonal evolution matched with drug response.en600 - Technology::610 - Medicine & health500 - Science::570 - Life sciences; biologyarticle10.48350/1818433707239010.1038/s41467-023-37696-2